The genomic testing platform developer has now raised some $140m, eight years after being co-founded in EPFL's Innovation Park by researchers from EMBL, Stanford and Geneva University.

Switzerland-based genomics technology provider Sophia Genetics has raised $77m in funding from investors led by investment firm Generation Investment Management.

Private equity firm Idinvest Partners, venture capital firm Balderton Capital and Alychlo, the investment vehicle for pharmaceutical entrepreneur Marc Coucke, also contributed to the round.

Founded in 2011, Sophia has developed a clinical genomics analytics platform intended to help healthcare professionals diagnose and treat patients for cancer and hereditary disorders by more thoroughly analysing genomic and radiomic data. It also provides a network that enables users to share genomic data.

It was launched in the Innovation Park of École polytechnique fédérale de Lausanne (EPFL) and its co-founders include Lars Steinmetz, senior scientist and group leader at EMBL and professor of genetics at Stanford University.

Pierre Hutter, who was co-director of Geneva University’s laboratory of predictive oncology until he became chief scientific officer of Sophia in 2011, and chief executive Jurgi Camblong also co-founded the company.

Sophia said the round boosted its overall funding to approximately $140m, and the latest cash injection will be used to expand the community of hospitals using its technology and grow its presence in the US as it looks to increase the size of its team.

The company completed a $30m series D round in 2017 that was led by Balderton and included 360º Capital Partners, Invoke Capital and Alychlo.

Invoke led a $13.8m series B round for Sophia in 2014 that was backed by telecoms firm Swisscom and Endeavour Vision, before Marc Coucke led the company’s $15m series C round the following year.

Camblong said: “Since we founded the company, our goal has been to help make the global healthcare system more sustainable.

“By helping clinical researchers leverage their expertise and work together as a community, patients all over the world can receive equal access to better care.”

– A version of this article first appeared on our sister site, Global Corporate Venturing.